Takeda to Divest TachoSil to Corza Health for ~$416M

Shots:

• Corza Health to acquire the assets and licenses supporting the development and commercialization of TachoSil while Takeda will retain its ownership of the manufacturing facility in Linz and Austria. The agreement is expected to be close by Mar 31, 2021
• In May’2019, Takeda and Ethicon collaborated for the sales of TachoSil. The two companies mutually terminate the transaction in Apr’2020 because of anti-trust concerns raised by the EC
• TachoSil is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control

Click here ­to­ read full press release/ article | Ref: Takeda | Image: The Malaysian Reserve